Latest News and Press Releases

aTyr Pharma Presents Additional Findings from Phase 3 EFZO-FIT™ Study in Late-Breaking Oral Abstract at the European Respiratory Society Congress 2025

Block & Leviton is investigating aTyr Pharma after the company announced that its Phase 3 trial for efzofitimod failed to meet its primary endpoint.

aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis

aTyr Pharma Announces Last Patient Visit in Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis

aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference

aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update

aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise

aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update

aTyr Pharma Announces Publication Demonstrating Efzofitimod’s Immunomodulatory Activity in Science Translational Medicine

aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis